Razupenem
Razupenem (PTZ-601) is a broad spectrum injectable antibiotic, from the carbapenem subgroup of beta-lactam antibiotics. It was developed as a replacement drug to combat bacteria that had acquired antibiotic resistance to commonly used antibiotics.[1] Razupenem performed well against a variety of bacterial strains,[2] but further development is in doubt due to a high rate of side effects in Phase II clinical trials.
Clinical data | |
---|---|
Trade names | PTZ-601 |
Routes of administration | IV |
Legal status | |
Legal status | |
Identifiers | |
IUPAC name
| |
ChemSpider | |
KEGG | |
Chemical and physical data | |
Formula | C18H21N3O4S2 |
Molar mass | 407.51 g/mol g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
References
- Livermore, D. M.; Mushtaq, S.; Warner, M. (2009). "Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms". Journal of Antimicrobial Chemotherapy. 64 (2): 330–335. doi:10.1093/jac/dkp187. PMID 19497942.
- Tran, C. M.; Tanaka, K.; Yamagishi, Y.; Goto, T.; Mikamo, H.; Watanabe, K. (2011). "In Vitro Antimicrobial Activity of Razupenem (SMP-601, PTZ601) against Anaerobic Bacteria". Antimicrobial Agents and Chemotherapy. 55 (5): 2398–2402. doi:10.1128/AAC.01038-10. PMC 3088197. PMID 21343447.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.